(Finance) – Erfo Pharmaceutical Laboratorya company operating in the nutraceutical sector and listed on Euronext Growth Milan, closed on 2023 with revenues equal to 6.18 million euros, up 23% compared to 31 December 2022 and 3% compared to pro-forma revenues at 31 December 2022. The number of Diètnatural brand centers active in Italy at 31 December 2023 is 119 (+2 YoY), of which 12 direct. The number of Bodysano brand centers as of 31 December 2023 is 30 (+3 YoY), of which 29 in France (in franchising) and one directly in Belgium, inaugurated on 16 January 2024, which will act as a pilot for the development of the network throughout the French-speaking area.
L’Adjusted EBITDA is equal to approximately 1.61 million euros, with aincidence equal to 26% of revenues, down 11% compared to 2022.
There NFP adjusted it is cash positive and equal to approximately 1.28 million euros, an improvement compared to 31 December 2022 when it was respectively equal to approximately 1 million euros. The company, in addition to having made investments linked to the opening of the new centers and, in general, to support growth, has used cash for non-recurring activities for approximately 0.60 million euros, such as the launch of the buyback plan and the payment of the agreed fee for the FarmaWow operation.
“2023 was a year characterized by structural evolutions which place us in a new dimension compared to the past and put us face to face with the new challenges that await us – commented theAD Alessandro Cutè – Total revenues – even without considering the consolidation of Erfo France acquired in January – are the highest ever. We now represent a vertically integrated group that operates at full capacity in Italy, France and Belgium with two distinctive brands, Diètnatural and BodySano, with important signs of growth in the Medical line through products intended for pharmacies and healthcare facilities (+96% of revenues YoY )”.